Royalty Pharma Plc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Royalty Pharma Plc's ROA in the third quarter of 2026?
Royalty Pharma Plc achieved a return on average assets (ROA) of 7.49 % in its third quarter of 2026, this is above RPRX's average return on assets of -39.69%.
Royalty Pharma Plcs assets during the 12 months ending in the third quarter of 2026 are valued at $12 billion

ROA fell compared to the second quarter of 2026, despite the net income growth of 77.55% from the second quarter of 2026.

However, within the Healthcare sector 139 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 1034, from total ROA ranking in the second quarter of 2026 at 1198.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	488.84 %	6.21 %	51.11 %	31.68 %	21.44 %
Y / Y Net Income Change	-49.1 %	153.25 %	8.03 %	-35.93 %	-64.75 %
Net Income (TTM) in million	909	1,048	999	964	1,084
Return On Assets (TTM)	7.49 %	13.25 %	13.13 %	13.21 %	15.34 %
RPRX's Total Ranking	# 1034	# 1198	# 914	# 705	# 629
Total Assets (TTM) in million	20,354	20,671	3,680	3,831	3,457
Seq. Total Assets Change	-1.53 %	461.74 %	-3.95 %	10.84 %	-82.24 %
Seq. Net Income Change	77.55 %	-82.6 %	118.6 %	-24.63 %	783.32 %

RPRX's 5 Years Annual ROA >> Back to RPRX Management Effectiveness >> Compare RPRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 52
Sector	# 140
Overall	# 1010

Return On Assets Statistics
High	Average	Low
15.43 %	-39.69 %	-230.49 %
(Sep 30 2020)		(Sep 30 2017)

Financial Statements
Royalty Pharma Plc's Assets	$ 20,354 million	RPRX's Balance sheet
Royalty Pharma Plc's Income	$ 145 million	Quarterly RPRX's Income Statement
RPRX's Income by Division		See RPRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	31.68 %	38.93 %	-34.74 %	-9.08 %	5.16 %
Total Assets in million	3,831	2,910	2,094	3,209	3,530
Y / Y Net Income Change	-0.5 %	-21.72 %	638.96 %	-81.46 %	-27.07 %
Net Income in million	1,324	1,331	1,700	230	1,241
Annual Return On Assets	34.56 %	45.74 %	81.18 %	7.17 %	35.16 %

RPRX's 5 Years Annual ROA >> Back to RPRX Management Effectiveness >> Compare RPRX ROA to its Competitors

Comment on RPRX's ROA in the fiscal year ending 2025

In the fiscal year 2025 Royalty Pharma Plc's ROA decreased compared to previous year to 34.56 %, due to deterioration of net income -0.5 % to $1,324.19 million, from $1,330.81 million a year ago, as RPRX's assets were $3,831.30 million.

More Return On Assets Ratios
RPRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RPRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RPRX's Competitors
Subscribers only: Roa for Royalty Pharma Plc's Suppliers
Subscribers only: Return On Assets for RPRX's Customers

You may also want to know
RPRX's Roi	RPRX's Inventory Turnover Ratio	RPRX's Growth Rates	RPRX's Dividend Comparisons
	RPRX's Profitability Ratios	RPRX's Asset Turnover Ratio	RPRX's Dividend Growth
RPRX's Roe	RPRX's Valuation Ratios	RPRX's Financial Strength Ratios	RPRX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %
Msa Safety Inc	11.01 %
Encompass Health Corporation	10.99 %
Inspire Medical Systems inc	10.89 %
Transmedics Group Inc	10.67 %
Bristol myers Squibb Company	10.47 %
Lemaitre Vascular Inc	10.28 %
Beone Medicines Ltd	10.23 %
Amgen Inc	10.02 %
Bio rad Laboratories Inc	9.88 %

Date modified: 2026-11-06T13:04:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.